They found that PALB2 carriers were not more common in prostate cancer patients overall, but were common in those diagnosed with aggressive prostate cancers of high grade (Gleason score 8–10) than noncarriers (64.3% vs. 18.1%, p < 0.0001). The gene discussed is PALB2; the disease is prostate carcinoma.